Deborah J. Wong, MD, PhD

1. Wong, D.L., Rao, A.,  Avramis, E., Matsunaga, D.R , Komatsubara, K.M., Chodon, T. , Koya, R.C., Ribas, A.  and Comin-Anduix, B.  Detrimental Effects of a Histone Deacetylase Inhibitor on Human Lymphocytes.  Cancer Immunol Res, 2014, May 2014 2; 459.
2. Atefi, M., Avramis, E., Lassen, A., Wong, D.J., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T.G., Comin-Anduix, B., Ribas, A., Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma. Clinical Cancer Research. 2014, May 8. PMID: 24812408.
3. Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2014 Aug 20;13:194. PMID: 25142146.
4. Atefi, M.S., Titz, B., Avramis, E., Ng, C., Wong, D.J.L., Lassen, A., Cerniglia, M., Escuin-Ordinas, H., Foulad, D., Comin-Anduix, B., Graeber, T., and Ribas, A.  Combination of Pan-RAF and MEK inhibitors in NRAS mutant melanoma cell lines. Mol Cancer. 2015 Feb 3;14:27. PMID: 25645078
5. Warner WA, Wong DJ, Palma-Diaz F, Shibuya TY, Momand J. Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion.(Link is external) Case Rep Oncol Med. 2015;2015:  PMID:  26634163
6. Hu, S.B. Wong, D.J.L., Anath, A., Li, N., and Deng, J.C.  Prediction of Clinical Deterioration in Hospitalized Adult Patients with Hematologic Malignancies Using a Neural Network Model.  PLOS One, 2016 Aug 17;11(8). PMID: 27532679
7. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR.  Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.(Link is external)  J Clin Oncol. 2016 Aug 15. PMID: 27528724.
8. Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, Beron P, Wong D, Rosove MH, Rao S, Melanson H, Kim E, Palmer D, Qi L, Kelly K, Steinberg ML, Kupelian PA, Daly ME.  Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.(Link is external)  Lancet Oncol. 2017 Apr 20. pii: S1470-2045(17)30246-2. PMID:  28434660.
9. Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJL, Leach J, Edenfield WJ, Wang D, Grote HJ, Heydebreck AV, Chin K, Cuillerot JM, Kelly K.  Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.(Link is external)  Lancet Oncol. 2017 May;18(5):599-610.  PMID:  28373005.
10. Spiegel ML(Link is external), Goldman JW(Link is external), Wolf BR(Link is external), Nameth DJ(Link is external), Grogan TR(Link is external), Lisberg AE(Link is external), Wong DJL(Link is external), Ledezma BA(Link is external), Mendenhall MA(Link is external), Genshaft SJ(Link is external), Gutierrez AJ(Link is external), Abtin F(Link is external), Wallace WD(Link is external), Adame CR(Link is external), McKenzie JR(Link is external), Abarca PA(Link is external), Li AJ(Link is external), Strunck JL(Link is external), Famenini S(Link is external), Carroll JM(Link is external), Tucker DA(Link is external), Sauer LM(Link is external), Moghadam NM(Link is external), Elashoff DA(Link is external), Abaya CD(Link is external), Brennan MB(Link is external), Garon EB(Link is external).  Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer.(Link is external) 2017 Dec 15;123(24):4800-4807.  PMID: 29125624.
11. Hegde JV, Shaverdian N, Daly ME, Felix C, Wong DL, Rosove MH, Garst JH, Wang PC, Veruttipong D, Rao S, Fragoso RC, Riess JW, Steinberg ML, Chen AM.  Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial.(Link is external) Cancer. 2017 Oct 17. PMID: 29044458
12. Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCerescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.  First-in-class ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose escalation and expansion study.  Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.  PMID: 29247021.
13. Atkins M, Hodi FS, Thompson J, McDermott D, Hwu W, Lawrence D, Dawson N, Wong D, Bhatia S, JamesM, Jain L, Robey S, Shu X, Homet Moreno B, Perini R, Choueiri T, and Ribas A.  Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase 1b KEYNOTE-029 study.   Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22. PMID 29358500
14. Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I, Gulley JL.  Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN Solid Tumor and phase 2 JAVELIN Merkel 200 clinical trials.  Cancer 2018 May 1;124(9):2010-2017. doi: 10.1002/cncr.31293. Epub 2018 Feb 22.PMID 29469949
15. Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, Braas D, Grasso CS, Palaskas N, Ribas A, Graeber TG.  Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.(Link is external) Cancer Cell. 2018 May 14;33(5):890-904.e5. doi: 10.1016/j.ccell.2018.03.017. Epub 2018 Apr 12.PMID 29657129.
16. Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS.  SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.(Link is external)  Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28. PMID  30154193.

See more publications.

• My Turn: What to expect if you hear those dreaded words: You have cancer(Link is external) (Link opens in new window) (Daily Breeze)
• Accessing a Clinical Trial for Stage IV Medullary Thyroid Cancer During the Pandemic - Cancer Progress Report(Link is external) (Link opens in new window) (aacr.org)

• 022aode.com/community-cancercare(Link is external)
• 022aode.com/community-cancercare/santa-monica
• 022aode.com/community-cancercare/torrance
• 022aode.com/community-cancercare/westwood(Link is external)
• 022aode.com/lungcancer
• 022aode.com/torrance